Ustekinumab poised to enter the psoriasis market.
Schmidt
Charlie
C
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017277:Drug Approval; D006801:Humans; D018664:Interleukin-12 / Q000037:antagonists & inhibitors / Q000276:immunology*; D053759:Interleukin-23 / Q000037:antagonists & inhibitors / Q000276:immunology*; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D014481:United States; D014486:United States Food and Drug Administration; D000069549:Ustekinumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053759:Interleukin-23; D018664:Interleukin-12; D000069549:Ustekinumab